Amyotrophic Lateral Sclerosis
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Drugs by status
Approved for this indication (5)
Phase 4 trials (4)
Phase 3 trials (51)
- masitinib
- abacavir
- acetylcarnitine
- vitamin e
- arimoclomol
- copper
- valproic acid
- escitalopram
- dolutegravir
- bone marrow derived mesenchymal stem cells
- i-123-adam
- ibudilast
- mecasermin
- deferiprone
- ioflupane i-123
- lamivudine
- levosimendan
- lithium
- memantine
- rimabotulinumtoxinB
- olanzapine
- Olesoxime
- sodium phenylbutyrate
- pridopidine
- quinidine
- ceftriaxone
- cannabis
- tirasemtiv
- trazodone
- trehalose
- +21 more
Phase 2 trials (140)
- fingolimod
- metformin
- melatonin
- 124i-pu-ad
- thalidomide
- 3k3a-apc
- methylprednisolone
- corticotropin
- ambroxol
- anx005
- astaxanthin
- beta-hydroxybutyrate
- epoetin
- blz945
- cistanche total glycosides
- creatinine
- cromoglicic acid
- darifenacin
- prednisone
- dextran
- perampanel
- troloxamide
- ezogabine
- tacrolimus
- somatropin
- leuprolide
- trametinib
- aldesleukin
- albumin (Human)
- ic14
- +110 more
Phase 1 trials (74)
- 18f-x
- pbr28
- 18f-pbr06
- dpa 714
- acamprosate
- bhv-0223
- capsaicin
- cc100
- tofacitinib
- betamethasone
- gdc-0134
- ritonavir
- cobalamin
- bosutinib
- levodopa
- carbidopa
- isis 333611
- allogeneic stem cells
- oxaloacetate
- lidocaine
- caffeine
- immune globulin (human)
- siplizumab
- abatacept
- terazosin
- darunavir
- rabeprazole
- itraconazole
- thiamine
- autologous mesenchymal stem cell-derived neural progenitors
- +44 more
Other trials (17)
- 18f ge-180
- alpha-lipoic acid
- fiber
- palmitoylethanolamide
- dronabinol
- niacin
- peripheral blood lymphocytes
- pterostilbene
- nicotinamide
- autologous umbilical cord blood
- ipsc
- prebiotic fiber
- long-chain triglyceride
- amino acids
- fludeoxyglucose f-18
- 1-(beta-d-ribofuranosyl)nicotinamide chloride
- 3,5-dimethoxy-4'-hydroxy-trans-stilbene
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (74)
- AB Science
- Eisai
- Cephalon
- Trophos
- MediciNova
- Roche
- Avanir
- Biogen
- Alexion
- Amylyx Pharmaceuticals Inc.
- Brainstorm Cell Therapeutics
- INC Research
- Laboratoire français de Fractionnement et de Biotechnologies
- Knopp Biosciences
- Orphazyme
- Ra Pharmaceuticals
- The Avicena Group
- Collaborative Medicinal Development Pty Limited
- Cytokinetics
- National Institute of Neurological Disorders and Stroke (NINDS)
- Cedars-Sinai Medical Center
- University of London
- Harvard University
- Katholieke Universiteit Leuven
- NHS Lothian
- Okayama University
- Sheffield Hallam University
- Universidad Autonoma de Nuevo Leon
- University of Edinburgh
- University of Kansas
- +44 more
Organization Involved with Phase 2 Indications (145)
- Celgene
- Forest Laboratories
- Astellas
- Gilead Sciences
- Genentech
- Grifols
- Pfizer
- Apotex
- AZTherapies, Inc.
- Novartis
- Allergan
- Corestem, Inc.
- Bioelectron
- Flex Pharma, Inc.
- GlaxoSmithKline
- Implicit Bioscience
- Mallinckrodt
- Merz
- Phoenix Neurological Associates, LTD
- Teva
- Apellis Pharmaceuticals, Inc.
- CytRx
- Genervon Biopharmaceuticals, LLC
- Neuraltus Pharmaceuticals, Inc.
- Q Therapeutics, Inc.
- Stem Cells Arabia
- Center for Neurologic Study, La Jolla, California,
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- IRCCS National Neurological Institute C. Mondino Foundation
- Muscular Dystrophy Association
- +115 more
Organization Involved with Phase 1 Indications (30)
- Chemigen, LLC
- Cognitive Research Corporation
- Ionis Pharmaceuticals, Inc.
- Molecular NeuroImaging
- Red de Terapia Celular
- TCA Cellular Therapy
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Polish Academy of Sciences
- Shahid Beheshti University of Medical Sciences
- Hospital e Maternidade Dr. Christóvão da Gama
- Rockefeller University
- Medical University of Warsaw
- Royan Institute
- Spanish National Health System
- Universidad de Murcia
- François Rabelais University
- University of Toulouse
- Quotient
- University of Missouri
- Shahed University
- University of Queensland
- University of Perugia
- Clinica Jordy Sinapse
- Public Health Service, Murcia
- Hackensack University Medical Center
- Everfront Biotech Co., Ltd.
- Denali Therapeutics Inc.
- AL-S Pharma
- Rapa Therapeutics LLC
- Band of Hope Foundation
Organization Involved with Other Experimental Indications (15)
- Elysium Health
- University of Roma La Sapienza
- Campus Bio-Medico University
- D'Annunzio University of Chieti–Pescara
- University of Florence
- University of Nebraska
- University of Valencia
- Stony Brook University
- Dalian Medical University
- Zhejiang University
- Cha Medical University
- Cantonal Hospital of St. Gallen
- Avera Health
- Nanjing 1718 Biotech Co. Ltd
- Jiangsu University